Compare AbCellera Biologics Inc (ABCL) vs Comfort Systems USA Inc (FIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Comfort Systems USA Inc — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Comfort Systems USA Inc trades at $1,678.61 (market cap $59.26B). The key difference: Comfort Systems USA Inc is far larger — about 25.2× AbCellera Biologics Inc's market cap, and Comfort Systems USA Inc pays a 0.15% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | FIX | |
|---|---|---|
Market Cap | $2.35B | $59.26B |
Sector | Health | Technology |
52-Week High | $8.12 | $2.07K |
52-Week Low | $2.78 | $527.42 |
Enterprise Value | $1.99B | $58.55B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Comfort Systems USA (FIX) trades at $1,793.03, up 2.97% with strong earnings momentum as Q1 2026 EPS of $10.51 beat expectations of $6.81. The stock shows bearish technical signals but maintains robust fundamentals with 2025 revenue of $9.10B and net income of $1.02B. Recent news highlights leadership transitions and data center cooling demand driving growth.
Outlook remains positive with analyst consensus price target of $2,080 representing 16% upside potential. Key risks include execution challenges from record backlog and competitive pressures in HVAC infrastructure. The company's strong cash flow generation supports dividend payments and strategic acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →
